A review of the DTaP-IPV-HB-PRP-T Hexavalent vaccine in pediatric patients

References

• Skibinski DA, Baudner BC, Singh M, et al. Combination vaccines. J Glob Infect Dis. 2011;3(1):63–72.
   PubMedGoogle Scholar
• Obando-Pacheco P, Rivero-Calle I, Gómez-Rial J, et al. New perspectives for hexavalent vaccines. Vaccine. 2018;36(36):5485–5494.
   PubMed Web of Science ®Google Scholar
• Woodin KA, Rodewald LE, Humiston SG, et al. Physician and parent opinions. Are children becoming pincushions from immunizations? Arch Pediatr Adolesc Med. 1995;149(8):845–849.
   PubMedGoogle Scholar
• European Medicines Agency. Public statement on hexavac: withdrawal of marketing authorisation in the European Union. 2012 [cited 2022 Dec 23]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/hexavac
   Google Scholar
• Dolhain J, Janssens W, Mesaros N, et al. Hexavalent vaccines: increasing options for policy-makers and providers. A review of the data supporting interchangeability (substitution with vaccines containing fewer antigens) and mixed schedules from the same manufacturer. Expert Rev Vaccines. 2018;17(6):513–524.
   PubMed Web of Science ®Google Scholar
• World Health Organisation. Table 2: summary of WHO position papers - recommended routine immunizations for children. (2021). https://www.who.int/docs/default-source/immunization/immunization_schedules/immunization-routine-table2
   Google Scholar
• European Medicines Agency. Hexyon: EPAR - Product Information. 2022 [cited 2022 Dec 23]. https://www.ema.europa.eu/en/documents/product-information/hexyon-epar-product-information_en.pdf
   Google Scholar
• Syed YY. DTaP-IPV-HepB-Hib vaccine (hexyon®): an updated review of its use in primary and booster vaccination. Paediatr Drugs. 2019;21(5):397–408.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Immunological basis for immunization: module 2: diphtheria - update 2009 [cited 2022 Dec 23]. https://apps.who.int/iris/bitstream/handle/10665/44094/9789241597869_eng.pdf?sequence=1&isAllowed=y
   Google Scholar
• United Kingdom Health Security Agency. Public health control and management of diphtheria in England: 2022 Guidelines. 2022 [cited 2022 Dec 23]. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1083946/Diphtheria-guidelines-2022-v16.1.pdf
   Google Scholar
• World Health Organization. Diphtheria vaccine: WHO position paper, August 2017 - recommendations. Vaccine. 2018;36(2):199–201.
   PubMed Web of Science ®Google Scholar
• United Kingdom Health Security Agency. Diphtheria. In: The Green Book: Immunisation against infectious disease. 2013 [cited 2022 Dec 23]. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/147952/Green-Book-Chapter-15.pdf
   Google Scholar
• Kyu HH, Mumford JE, Stanaway JD, et al. Mortality from tetanus between 1990 and 2015: findings from the global burden of disease study 2015. BMC Public Health. 2017;17(1):179.
   PubMedGoogle Scholar
• Collins S, Amirthalingam G, Beeching NJ, et al. Current epidemiology of tetanus in England, 2001-2014. Epidemiol Infect. 2016;144(16):3343–3353.
   PubMed Web of Science ®Google Scholar
• United Kingdom Health Security Agency. Tetanus in England: 2021 - GOV.UK [Internet]. 2021 [cited 2022 Dec 23]. Available from: https://www.gov.uk/government/publications/tetanus-in-england-annual-reports/tetanus-in-england-2021.
   Google Scholar
• World Health Organization. The immunological basis for immunization series: module 3: tetanus. World Health Org. 2018. https://apps.who.int/iris/bitstream/handle/10665/275340/9789241513616-eng.pdf?sequence=1&isAllowed=y
   Google Scholar
• World Health Organisation. Pertussis [Internet]. 2022 [cited 2022 Dec 23]. Available from: https://www.who.int/health-topics/pertussis.
   Google Scholar
• European Centre for Disease Prevention and Control. Pertussis In: ECDC. Annual epidemiological report for 2018. 2020 [cited 2022 Dec 23]. https://www.ecdc.europa.eu/en/publications-data/pertussis-annual-epidemiological-report-2018#:~:text=Pertussis%20In%3A%20ECDC.-,Annual%20epidemiological%20report%20for,Stockholm%3A%20ECDC%3B%202020.&text=In%202018%2C%20there%20were%2035,72%25%20of%20all%20notified%20cases
   Google Scholar
• United Kingdom Health Security Agency. Laboratory confirmed cases of pertussis in England: annual report for 2021 - GOV.UK [Internet]. 2022 [cited 2022 Dec 23]. Available from: https://www.gov.uk/government/publications/pertussis-laboratory-confirmed-cases-reported-in-england-2021/laboratory-confirmed-cases-of-pertussis-in-england-annual-report-for-2021.
   Google Scholar
• World Health Organization. The immunological basis for immunization series: module 4: pertussis. World Health Org. 2010. https://apps.who.int/iris/bitstream/handle/10665/259388/9789241513173-eng.pdf?sequence=1&isAllowed=y
   Google Scholar
• World Health Organisation. Poliomyelitis [Internet]. 2022 [cited 2022 Dec 23]. Available from: https://www.who.int/news-room/fact-sheets/detail/poliomyelitis.
   Google Scholar
• Bandyopadhyay AS, Garon J, Seib K, et al. Polio vaccination: past, present and future. Future Microbiol. 2015;10(5):791–808.
   PubMed Web of Science ®Google Scholar
• Mehndiratta MM, Mehndiratta P, Pande R. Poliomyelitis: historical facts, epidemiology, and current challenges in eradication. Neurohospitalist. 2014;4(4):223–229.
   PubMedGoogle Scholar
• Wise J. Poliovirus is detected in sewage from north and east London. BMJ. 2022;377:o1546.
   PubMedGoogle Scholar
• New York State Department. New York state department of health and rockland county department of health alert the public to a case of polio in the county. 2022 [cited 2022 Dec 23]. https://health.ny.gov/press/releases/2022/2022-07-21_polio_rockland_county.htm.
   Google Scholar
• Global Polio Laboratory Network. Short report on type 2 polioviruses detected in the USA, Israel and the UK. 2022 [cited 2022 Dec 23]. https://polioeradication.org/wp-content/uploads/2022/07/VP1-narrative-ISR-NY-UK-29072022.pdf
   Google Scholar
• Plotkin SA. Correlates of protection induced by vaccination. Clin Vaccine Immunol. 2010;17(7):1055–1065.
   PubMed Web of Science ®Google Scholar
• European Centre for Disease Prevention and Control. Haemophilus influenzae. ECDC. In: Annual epidemiological report for 2018.2020. https://www.ecdc.europa.eu/en/publications-data/haemophilus-influenzae-annual-epidemiological-report-2018
   Google Scholar
• World Health Organization. Immunological basis for immunization: haemophilus influenzae type b vaccines. 2007 [cited 2022 Dec 23]. https://www.who.int/publications/i/item/who-immunological-basis-for-immunization-series-module-9-haemophilus-influenzae-type-b
   Google Scholar
• World Health Organization. Hepatitis B [Internet]. 2022 [cited 2022 Dec 23]. Available from: https://www.who.int/news-room/fact-sheets/detail/hepatitis-b.
   Google Scholar
• World Health Organization. The immunological basis for immunization series: module 22: hepatitis B. 2011 [cited 2022 Dec 23]. https://www.who.int/publications/i/item/who-immunological-basis-for-immunization-series-module-22-hepatitis-b
   Google Scholar
• Sanofi. Clinical study results pasteur - sanofi [Internet]. 2022 [cited 2022 Dec 23]. Available from: https://www.sanofi.com/en/science-and-innovation/clinical-trials-and-results/our-disclosure-commitments/pasteur
   Google Scholar
• Madhi SA, Mitha I, Cutland C, et al. Immunogenicity and safety of an investigational fully liquid hexavalent combination vaccine versus licensed combination vaccines at 6, 10, and 14 weeks of age in healthy South African infants. Pediatr Infect Dis J. 2011;30(4):68–74.
   PubMed Web of Science ®Google Scholar
• Tregnaghi MW, Zambrano B, Santos-Lima E. Immunogenicity and safety of an investigational hexavalent diphtheria-tetanus-acellular pertussis-inactivated poliovirus-hepatitis B-Haemophilus influenzae b conjugate combined vaccine in healthy 2-, 4-, and 6-month-old Argentinean infants. Pediatr Infect Dis J. 2011;30(6):88–96.
   PubMed Web of Science ®Google Scholar
• Tregnaghi M, Zambrano B, Santos-Lima E. Antibody persistence after a primary series of a new DTaP-IPV-Hep B-PRP-T combined vaccine or separate DTaP-IPV//PRP-T and hepatitis B vaccines at 2, 4, and 6 months of age and the effect of a subsequent DTaP-IPV//PRP-T booster vaccination at 18 months of age in healthy Argentinean infants. Pediatr Infect Dis J. 2012;31(1):24–30.
   PubMed Web of Science ®Google Scholar
• Aquino AGB, Brito MG, Doniz CEA, et al. A fully liquid DTaP-IPV-Hep B-PRP-T hexavalent vaccine for primary and booster vaccination of healthy mexican children. Vaccine. 2012;30(45):6492–6500.
   PubMed Web of Science ®Google Scholar
• Vesikari T, Silfverdal S-A, Jordanov E, et al. A randomized, controlled study of DTaP-IPV-HB-PRP-T, a fully liquid hexavalent vaccine, administered in a 3-, 5- and 11- to 12-month schedule. Pediatr Infect Dis J. 2017;36(1):87–93.
   PubMed Web of Science ®Google Scholar
• Kim Y-K, Vidor E, Kim HM, et al. Immunogenicity and safety of a fully liquid DTaP-IPV-HB-PRP∼T hexavalent vaccine compared with the standard of care in infants in the Republic Of Korea. Vaccine. 2017;35(32):4022–4028.
   PubMed Web of Science ®Google Scholar
• Ceyhan M, Yıldırım İ, Tezer H, et al. A fully liquid DTaP-IPV-HB-PRP-T hexavalent vaccine for primary and booster vaccination of healthy Turkish infants and toddlers. Turk J Med Sci. 2017;47(4):1247–1256.
   PubMed Web of Science ®Google Scholar
• López P, Arguedas Mohs A, Abdelnour Vásquez A, et al. A randomized controlled study of a fully liquid DTaP-IPV-HB-PRP-T Hexavalent vaccine for primary and booster vaccinations of healthy infants and toddlers in Latin America. Pediatr Infect Dis J. 2017;36(11):272–282.
   PubMed Web of Science ®Google Scholar
• Kosalaraksa P, Thisyakorn U, Benjaponpitak S, et al. Immunogenicity and safety study of a new DTaP-IPV-Hep B-PRP-T combined vaccine compared to a licensed DTaP-IPV-Hep B//PRP-T comparator, both concomitantly administered with a 7-valent pneumococcal conjugate vaccine at 2, 4, and 6 months of age in Thai infants. Int J Infect Dis. 2011;15(4):249–256.
   PubMed Web of Science ®Google Scholar
• Prymula R, Kieninger D, Feroldi E, et al. Immunogenicity and safety of primary and booster vaccinations of a fully liquid DTaP-IPV-HB-PRP-T Hexavalent vaccine in healthy infants and toddlers in Germany and the Czech Republic. Pediatr Infect Dis J. 2018;37(8):823–830.
   PubMed Web of Science ®Google Scholar
• Madhi SA, Koen A, Cutland C, et al. Antibody persistence and booster vaccination of a fully liquid hexavalent vaccine coadministered with measles/mumps/rubella and varicella vaccines at 15-18 months of age in healthy South African infants. Pediatr Infect Dis J. 2013;32(8):889–897.
   PubMed Web of Science ®Google Scholar
• Macías M, Lanata CF, Zambrano B, et al. Safety and immunogenicity of an investigational fully liquid hexavalent DTaP-IPV-Hep B-PRP-T vaccine at two, four and six months of age compared with licensed vaccines in Latin America. Pediatr Infect Dis J. 2012;31(8):126–132.
   PubMed Web of Science ®Google Scholar
• Lanata C, Zambrano B, Ecker L. Immunogenicity and safety of a fully liquid DTaP-IPV-Hep B-PRP-T vaccine at 2-4-6 months of age in peru. J Vaccines Vaccin. 2012;3(1). https://www.walshmedicalmedia.com/open-access/immunogenicity-and-safety-of-a-fully-liquid-dtap-ipv-hep-b-prp-t-vaccine-at-2-4-6-months-of-age-in-peru-2157-7560.1000128.pdf.
   Google Scholar
• Vesikari T, Borrow R, Da Costa X, et al. Concomitant administration of a fully liquid, ready-to-use DTaP-IPV-HB-PRP-T hexavalent vaccine with a meningococcal serogroup C conjugate vaccine in infants. Vaccine. 2017;35(3):452–458.
   PubMed Web of Science ®Google Scholar
• Vesikari T, Borrow R, Da Costa X, et al. Concomitant administration of a fully liquid ready-to-use DTaP-IPV-HB-PRP-T hexavalent vaccine with a meningococcal ACWY conjugate vaccine in toddlers. Vaccine. 2018;36(52):8019–8027.
   PubMed Web of Science ®Google Scholar
• Chhatwal J, Lalwani S, Vidor E. Immunogenicity and safety of a liquid hexavalent vaccine in Indian infants. Indian Pediatr. 2017;54(1):15–20.
   PubMed Web of Science ®Google Scholar
• Martinón-Torres F, Diez-Domingo J, Feroldi E, et al. Evaluation of a hexavalent-pentavalent-hexavalent infant primary vaccination series followed by a pentavalent booster vaccine in healthy infants and toddlers. Pediatr Infect Dis J. 2019;38(3):317–322.
   PubMed Web of Science ®Google Scholar
• Koen A, Madhi S, Lyabis O, et al. Immunogenicity and safety of a hexavalent pediatric vaccine in HIV-exposed infected and uninfected infants in Republic of South Africa. Hum Vaccin Immunother. 2012;17(6):1770–1778.
   Google Scholar
• Sanofi. Immunogenicity and safety of sanofi pasteur’s combined vaccine given as a three-dose primary series at 2, 3,4 months of age and followed by a booster dose given at 16 to 17 months of age in vietnamese infants who previously received a dose of Hepatitis B vaccine at birth or within 1 week after birth - full text view - clinicaltrials.gov [Internet]. 2022 [cited 2022 Dec 23]. https://www.clinicaltrials.gov/ct2/show/NCT02428491?term=A3L35&rank=1.
   Google Scholar
• Sanofi. EudraCT number 2013-003267-55 - clinical trial results - eu clinical trials register [internet]. 2017 [cited 2022 Dec 23]. https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-003267-55/results.
   Google Scholar
• Kosalaraksa P, Chokephaibulkit K, Benjaponpitak S, et al. Persistence of hepatitis B immune memory until 9-10 years of age following hepatitis B vaccination at birth and DTaP-IPV-HB-PRP∼T vaccination at 2, 4 and 6 months. Hum Vaccin Immunother. 2018;14(5):1257–1265.
   PubMed Web of Science ®Google Scholar
• Madhi SA, López P, Zambrano B, et al. Antibody persistence in pre-school children after hexavalent vaccine infant primary and booster administration. Hum Vaccin Immunother. 2019;15(3):658–668.
   PubMed Web of Science ®Google Scholar
• Virta M, Soininen A, Patel DM, et al. Persistence of hepatitis B immune memory until 6 years of age following hexavalent DTaP-IPV-HB-PRP~T vaccination in a 3-, 5- and 11- to 12-month schedule and response to a subsequent Hepatitis B challenge vaccination. Pediatr Infect Dis J. 2021;40(1):28–30.
   Web of Science ®Google Scholar
• Borrow R, Dagan R, Zepp F, et al. Glycoconjugate vaccines and immune interactions, and implications for vaccination schedules. Expert Rev Vaccines. 2011;10(11):1621–1631.
   PubMed Web of Science ®Google Scholar
• Knuf M, Haas H, Garcia-Corbeira P, et al. Hexavalent vaccines: what can we learn from head-to-head studies? Vaccine. 2021;39(41):6025–6036.
   PubMed Web of Science ®Google Scholar
• Mukherjee P, Hervé Akpo E, Kuznetsova A, et al. Hexavalent vaccines in infants: a systematic literature review and meta-analysis of the solicited local and systemic adverse reactions of two hexavalent vaccines. Expert Rev Vaccines. 2021;20(3):319–330.
   PubMed Web of Science ®Google Scholar
• Harriman K, Healy CM. How important is the type of acellular pertussis vaccine? Clin Infect Dis. 2020;70(2):208–209.
   PubMed Web of Science ®Google Scholar
• Tregnaghi MW, Voelker R, Santos-Lima E, et al. Immunogenicity and safety of a novel yeast Hansenula polymorpha-derived recombinant Hepatitis B candidate vaccine in healthy adolescents and adults aged 10-45 years. Vaccine. 2010;28(20):3595–3601.
   PubMed Web of Science ®Google Scholar
• Lee YH, Harris RC, Oh HW, et al. Vaccine-related errors in reconstitution in south korea: a national physicians’ and nurses’ survey. Vaccines (Basel). 2021;9(2):117.
   PubMed Web of Science ®Google Scholar
• De Coster I, Fournie X, Faure C, et al. Assessment of preparation time with fully-liquid versus non-fully liquid paediatric hexavalent vaccines. A time and motion study. Vaccine. 2015;33(32):3976–3982.
   PubMed Web of Science ®Google Scholar
• Lloyd AJ, Nafees B, Ziani E, et al. What are the preferences of health care professionals in Germany regarding fully liquid, ready-to-use hexavalent pediatric vaccine versus hexavalent pediatric vaccine that needs reconstitution? Patient Prefer Adherence. 2015;9:1517–1524.
   PubMed Web of Science ®Google Scholar
• Bakhache P, Virey B, Bienenfeld C. Knowledge and practices regarding infant vaccination: results of a survey of French physicians. Eur J Pediatr. 2019;178(4):533–540.
   PubMed Web of Science ®Google Scholar
• Martinelli D, Fortunato F, Del Matto G, et al. Post-marketing surveillance study of the DTaP2-IPV-HB-Hib (Hexyon) vaccine administered in preterm infants in the Apulia region, Italy, in 2017. Vaccine. 2020;38(33):5148–5153.
   PubMed Web of Science ®Google Scholar
• Gustafsson L, Hallander HO, Olin P, et al. A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine. N Engl J Med. 1996;334(6):349–355.
   PubMed Web of Science ®Google Scholar